Compositions and methods for reducing laminitis of an animal hoof

Abstract

A therapeutic composition for topical delivery of a metalloporphyrin to the hoof region of an equine leg suffering from laminitis is provided. Also provided is a method of reducing the degree of an injury to the hoof of an equine that is the result of laminitis. The method results in a reduced period for recovery and reduces the possibility of euthanasia of the animal.

What is claimed is: 
     
         1 . A method of ameliorating the adverse effects of equine laminitis comprising:
 topically administering to an equine having a laminitis injury an effective amount of a therapeutic composition, wherein the therapeutic composition comprises at least one manganese metalloporphyrin and a thickening or gelling agent dispersed in a penetrative carrier, wherein the therapeutic composition is administered to a region of the leg of the equine having the laminitis injury; and   continuing to administer the composition until the equine shows a reduction in the degree of injury due to laminitis.   
     
     
         2 . The method of  claim 1 , wherein the at least one manganese metalloporphyrin is selected from the group consisting of: manganese(III) meso-tetrakis(N-ethylpyridinium-2-yl) porphyrin chloride (BMX-010 or AEOL-10113), Manganese (III) meso-tetrakis (N, N′-diethylimidazolium-2-yl) porphyrin (AEOL-10150), Manganese (III) meso-tetrakis (N-ethylpyridinium-2-yl) porphyrin, Manganese (III) meso-tetrakis (2-pyridyl) porphyrin, Manganese (III) meso-tetrakis (3-pyridyl) porphyrin, Manganese (III) meso-tetrakis (4-pyridyl) porphyrin, Manganese (III) meso-tetraphenylporphyrin, Manganese (III) meso-tetrakis (N-alkylpyri-dinium-2-yl) porphyrin (AEOL-10112), Manganese (III) meso-tetrakis (N-alkylpyri-dinium-3-yl) porphyrin (AEOL-10113), Manganese (III) meso-tetrakis (N-alkylpri-dinium-4-yl) porphyrin, Manganese 5,10-bis(2-pyridyl)-15,20-bis(N-methylpyridinium-2-yl) porphyrin, Manganese 5-(2-pyridyl)-10,15,20-tris(N-methylpyridinium-2-yl) porphyrin, Manganese 5,10,15,20-tetrakis(2,3,5,6-tetrafluoro-N,N,N-trimethylanilinium-4-yl)porphyrin, Manganese (II) B-octabromo-meso-tetrakis(N-methylpyridinium-3-yl)porphyrin, Manganese (II) B-octabromo-meso-tetrakis(N-methylperidinium-4-yl)porphyrin, Manganese (III) B-(mono-tetra) chloro-meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, Manganese (II) B-pentacloro-meso-tetrakis(N-ethylpyridinium-4-yl)porphyrin, Manganese (III) meso-tetrakis (4-sulfonatophenyl)porphyrin, Manganese (III) meso-tetrakis (4-carboxylatophenyl)porphyrin, Manganese (III) B-octabromo-meso-tetrakis(4-sulfonatophenyl)porphyrin, Manganese (III) meso-tetrakis (2,6-dichlorvos-3-sulfonatophenyl)porphyrin, MnhemaoP(−). Hematoporphyrin IX, Iron (III) meso-tetrakis (4-carboxylatophenyl)porphyrin, Manganese (III) meso-tetrakis (N-methoxyethylpyridinium-2-yl)porphyrin, Manganese (III) meso-tetrakis [N,N′-di(2-methoxyethyl)imidazolium-2-yl]porphyrin, and Manganese (III) tetrakis [N-methyl-N′-methoxyethyl)imidazolium-2-yl)porphyrin. 
     
     
         3 . The method of  claim 1 , wherein the penetrative carrier is dimethyl sulfoxide. 
     
     
         4 . The method of  claim 1 , wherein the at least one manganese metalloporphyrin is manganese(III) meso-tetrakis(N-ethylpyridinium-2-yl) porphyrin chloride. 
     
     
         5 . The method of  claim 1 , wherein the therapeutic composition consists of manganese(III) meso-tetrakis(N-ethylpyridinium-2-yl) porphyrin chloride, dimethyl sulfoxide, and a thickening agent. 
     
     
         6 . The method of  claim 1 , wherein the therapeutic composition is applied daily for at least about one week, two weeks, three weeks, or four weeks.